Molina Healthcare enters its third-quarter report with a story that has two distinct halves. Its core government businesses appear to be healing, with Medicare duals running ahead of plan and Medicaid margins described as bottoming. Meanwhile, its Marketplace book keeps getting worse. Last quarter management raised full-year guidance for the first time in this cycle, but the raise was smaller than it could have been because Marketplace losses ate most of the gains elsewhere. The October 21 report, due after the close, should show which half of that story is gaining the upper hand.
The bar itself is low. Consensus calls for earnings of $0.73 a share on revenue of $10.93 billion. That would mean EPS falls about 60% from a year ago and revenue slips nearly 5%. It would also be a sharp step down from the $1.51 Molina earned in the second quarter. The Earnings Whisper sits at $0.80, modestly above consensus, which hints that some investors expect a small beat rather than a scrape past the number. For the full year, management guides to at least $5.25 a share, up from a floor of $5.00 that had held since the fourth-quarter report. Consensus of $5.23 sits essentially at the guidance floor. The Street is not leaning on management's upside, and it is barely giving full credit for the raise.
The most important evidence will come from the medical cost ratios by segment. In Medicare, management cut its full-year MCR outlook by 180 basis points to 92.2%. Duals ran near 92% and produced a first-year pre-tax margin of 1.4%, even though pricing had assumed a cautious 6% cost trend. If third-quarter duals results hold near that level, management's claim that the business can reach its 2.5% target margin early starts to look credible. Medicaid is the bigger earnings engine, guided to roughly $5.75 a share, and the reaffirmed 92.9% MCR is the number to defend. Management argued that the gap between 4% rate increases and 5% cost trend has stabilized. It also framed second-half margins outside Florida, around 1.9%, as the trough. Any slippage in Medicaid would undercut the central claim behind the improving tone.
Marketplace is where trust has to be rebuilt. Management lifted that segment's MCR guidance to 90% from 85.5% and now expects a $0.75 per share loss. It blamed members with costly drug needs, such as HIV and oncology patients, who stayed on the plan despite meaningful price gaps and were not offset by risk-adjustment revenue. Prior-year true-ups added further pressure. A third quarter consistent with the revised 90% would suggest the problem has been measured correctly. Another upward move would suggest the 30% repricing for 2026 was not enough, and would raise doubts about how the business is being repriced and shrunk for 2027. Updates on the 2027 premium outlook, recently trimmed to about $46.5 billion, and on readiness for the $6 billion Florida contract also matter. Management expects that contract to break even in its first full year.
The market has not rewarded the improved message. Shares are down 6.3% since the last report, trailing the S&P 500 by more than 11 percentage points. At $204.36, the stock sits roughly mid-range between its post-earnings low of $178 and high of $219.50, though comfortably above its 200-day moving average. Sentiment has warmed noticeably, rising to about 28.5% bullish from 3.1% a quarter ago. That suggests a more hopeful crowd than last time, even if the price has not followed.
Ultimately, this report hinges on whether Marketplace losses have stopped growing. If Medicaid and duals hold their ground and Marketplace stays within its revised guide, management's case that 2026 is the trough, with 2027 building blocks above $10 a share, keeps its footing. One more Marketplace surprise would make each new guidance raise look like a fragile netting exercise rather than a true recovery.